Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 19/20 | 0.66 |
| ▸ | SLC6A4 | P31645 | 16/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | HTR2C | P28335 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12459423 | 1.00 | SLC6A2 (0.66) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL14143440 | 0.88 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL15433976 | 0.88 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL12694069 | 0.88 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL2475580 | 0.86 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL15433977 | 0.85 | SLC6A2 (0.64) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL2722771 | 0.85 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL5527451 | 0.85 | SLC6A2 (0.67) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL141728 | 0.83 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL140633 | 0.81 | SLC6A3 (0.68) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE43879-E1 | Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug | PIERRE FABRE MEDICAMENT (FR) | 2012-12-25 | — | — | US | disclosed |
| EP-1485078-B1 | Milnacipran for the treatment of irritable bowel syndrome | CYPRESS BIOSCIENCE INC (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-1487787-B1 | DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS OF N-HYDROXYALKYL TETRAMETHYLCYCLOPROPANE-CARBOXAMIDE, HAVING ANTI-EPILEPTIC AND METHOD FOR THEIR PREPARATION | YISSUM RES DEV CO (IL) | 2010-12-22 | — | — | EP | disclosed |
| US-20050282859-A1 | Dual acting SNRI-NMDA antagonists for the treatment of genitourinary disorders | EDUSA PHARMACEUTICALS, INC. | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282859-A1 | Dual acting SNRI-NMDA antagonists for the treatment of genitourinary disorders | GRIN1, GRIN3A, GRM5 | SLC6A2 44/4885SLC6A4 144/4885SLC6A3 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.